PANACEA BIOTEC LIMITED

Highlights Panacea Biotec Limited

Equities

PANACEABIO

INE922B01023

Market Closed - NSE India S.E. Other stock markets 07:43:53 2024-05-24 am EDT			5-day change	1st Jan Change
136.8 ^INR	+0.33%		+0.44%	-18.52%

Apr. 13	Panacea Biotec Limited Appoints Ambika Sharma as Non-Executive Independent Director	CI
Apr. 01	Panacea Biotec Limited Announces the Cessation of Mr. Krishna Murari Lal, Mr. Namdeo Narayan Khamitkar and Mr. Raghava Lakshmi Narasimhan as Independent Directors	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Panacea Biotec Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 13	CI
Panacea Biotec Launches EasyFourPol® in India and Receives Registration of Valganciclovir Powder for Oral Solution in Germany	Dec. 14	CI
Panacea Biotec Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 10	CI
Panacea Biotec Launches Generic Cancer Treatment Drug in Canada	23-10-29	MT
Panacea Biotec's Arm Gets Nine Observations from US FDA	23-10-13	MT
Panacea Biotec Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-12	CI
Panacea Biotec Launches New Pediatric Food, Nutritional Products	23-06-15	MT
Panacea Biotec Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-30	CI
Panacea Biotec Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-30	CI
Panacea Biotec Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Panacea Biotec Limited Reports Earnings Results for the Nine Months Ended December 31, 2022	23-02-14	CI
Panacea Biotec Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
Ex-dividend day for final dividend	11-09-18	FA

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer